Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT ID: NCT06658730
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2025-06-19
2038-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Registry Characterizing the CTAG Device With ACTIVE CONTROL
NCT03286400
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865
Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
NCT00590759
Safety, Efficacy and Cost Analysis of the Conformable Thoracic Stent Graft With ACTIVE CONTROL
NCT04452240
Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic
NCT00874250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aneurysm/Other Isolated Lesion
Endovascular
TEVAR - thoracic endovascular aortic repair
Dissection
Endovascular
TEVAR - thoracic endovascular aortic repair
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endovascular
TEVAR - thoracic endovascular aortic repair
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient has been or is intended to be treated with an eligible registry device.\*
3. Patient is age ≥ 18 years at time of informed consent signature.
* The intent to treat a patient with a Gore product must be made prior to soliciting for possible registry participation. If pre-procedure consent is not feasible due to emergent situation, consent prior to the time of discharge for the index procedure is acceptable.
Exclusion Criteria
3. Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or investigational device study\* within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.
* The term "study" does not apply to other observational registries or quality improvement projects. Collection of Registry Device performance from interventional studies may be permissible provided device application is not investigational and there are no novel requirements that alter follow-up conduct (i.e., protocol-mandated interventions).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
W.L.Gore & Associates
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ali Azizzadeh, M.D.
Role: PRINCIPAL_INVESTIGATOR
Cedars-Sinai Medical Center
Timothy Resch
Role: PRINCIPAL_INVESTIGATOR
Univ. of CPH - Denmark
Kazuo Shimamura
Role: PRINCIPAL_INVESTIGATOR
Osaka University Hospital - Japan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars-Sinai Medical Center
Los Angeles, California, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Duke University
Durham, North Carolina, United States
Rigshospitalet
Copenhagen, , Denmark
Centre Hospitalier Universitaire Strasbourg
Strasbourg, , France
Regensburg University Hospital
Regensburg, , Germany
Laiko General Hospital of Athens
Athens, , Greece
Hospital Universitari de Bellvitge
Barcelona, , Spain
Uppsala University
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TGR 23-02TA
Identifier Type: OTHER
Identifier Source: secondary_id
TGR 23-02TA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.